Bayer Changes Pharma Leadership On Eve Of U.S. Stock Listing
This article was originally published in The Tan Sheet
Executive Summary
Bayer global pharmaceutical business head Wolfgang Plischke's range of experience within Bayer's different healthcare divisions is keeping with the company's plan to combine the divisions into a stand-alone unit
You may also be interested in...
Bayer Consumer Care Sale Remains Long-Term Option As Firm Restructures
Bayer AG is leaving open the possibility that it could sell its consumer care division in the long-term, while emphasizing that it remains part of its "core" businesses for now.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands